- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00344383
An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen
March 3, 2011 updated by: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
An Open-Label Study Evaluating the Bleeding Profile of Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) Administered as an Extended Regimen
The purpose of this study is to evaluate the bleeding profile of norgestimate/ethinyl estradiol, an oral contraceptive tablet, given in an extended regimen
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label study evaluating the bleeding profile of norgestimate/ethinyl estradiol tablets administered as an extended regimen (84 consecutive days of active tablets followed by seven days medication free) following a traditional regimen of two 28-day cycles (21 days of active tablets, followed by seven days of placebo tablets) of norgestimate/ethinyl estradiol tablets.
All patients will receive norgestimate/ethinyl estradiol tablets in a traditional regimen for two 28-day cycles.
Following the Traditional Treatment Phase, all patients will receive norgestimate/ethinyl estradiol tablets in an Extended Regimen Treatment Phase, consisting of 84 days of treatment with norgestimate/ethinyl estradiol tablets.
Safety evaluations include physical examinations, adverse event reporting and vital signs.
The hypothesis of the study is that a triphasic extended regimen would not result in breakthrough bleeding and spotting when the progestin dose drops.
Traditional Regimen: two 28 day cycles of norgestimate 180 mcg daily for 1 week, 215 mcg daily for 1 week, 250 mcg daily for 1 week, placebo daily for 1 week.
Extended Regimen: four uninterrupted cycles of norgestimate 180 mcg daily for 1 week, 215 mcg daily for 1 week, 250 mcg daily for 1 week, 1 week medication-free.
In both Treatment Regimens patients receive ethinyl estradiol 25 mcg in each active tablet.
The study is 147 days, Traditional days 1-56 and Extended days 57-147
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Subjects in good health as confirmed by medical history, physical exam, and PAP smear within the preceding six months
- Non-smokers, if between 35 and 45 years of age
- Patients who are not pregnant or lactating
- Had at least one normal menstrual period within 35 days prior to screening
- Completed their last term pregnancy at least 42 days prior to screening and had at least one normal menstrual period since the last pregnancy
- Must be post-menarcheal (have had at least one normal menstrual period) and pre-menopausal (having regular menstrual periods)
Exclusion Criteria:
- History or presence of disorders commonly accepted as contraindications to steroid hormonal therapy, eg, menopause, active or history of deep vein thrombophlebitis, thromboembolic disorders or hypercoagulation disorders, cerebral vascular or coronary artery disease, uncontrolled hypertension, or migraines with focal aura, benign or malignant liver tumor that developed during the use of oral contraceptives or estrogen-containing products
- carcinoma of any body system, diabetes mellitus with vascular involvement, known or suspected estrogen-dependent neoplasia, cholestatic jaundice, undiagnosed abnormal vaginal bleeding, neurovascular lesion of the eye, clinically relevant impairment of liver function, liver disease or renal disease
- absence of cyclic bleeding for at least three months, recent history of alcohol or other substance abuse
- significant depression or psychiatric disease that would result in an unreliable patients
- any subject deemed by the investigator to have questionable reliability in her ability to comply with the protocol and provide accurate information.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary efficacy variables include the number of breakthrough bleeding and/or spotting days during the extended regimen treatment phase and the number of breakthrough bleeding days during the extended regimen treatment phase.
|
Secondary Outcome Measures
Outcome Measure |
---|
Secondary efficacy variables include the number of bleeding and/or spotting days, number of bleeding days, number of bleeding and/or spotting episodes, and number of bleeding episodes during both treatment regimens
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2003
Study Completion (ACTUAL)
July 1, 2004
Study Registration Dates
First Submitted
June 23, 2006
First Submitted That Met QC Criteria
June 23, 2006
First Posted (ESTIMATE)
June 26, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
March 4, 2011
Last Update Submitted That Met QC Criteria
March 3, 2011
Last Verified
March 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Uterine Hemorrhage
- Hemorrhage
- Metrorrhagia
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Estradiol
- Ethinyl Estradiol
- Norgestimate
Other Study ID Numbers
- CR008344
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metrorrhagia
-
Ain Shams UniversityCompletedPremenopausal; MetrorrhagiaEgypt
-
Columbia UniversityCompletedMetrorrhagiaUnited States
-
McNeil Consumer & Specialty Pharmaceuticals, a...Completed
-
University of HawaiiMeharry Medical College; Charles Drew University of Medicine and ScienceCompletedBreakthrough BleedingUnited States
-
Brugmann University HospitalCompletedMetrorrhagiaBelgium
-
Eurofarma Laboratorios S.A.Withdrawn
-
Duramed ResearchCompletedBreakthrough BleedingUnited States
-
Oregon Health and Science UniversityCompletedBreakthrough BleedingUnited States
-
Oregon Health and Science UniversityMerck Sharp & Dohme LLCActive, not recruitingBleeding | Breakthrough Bleeding | ImplantsUnited States
-
University of Sao PauloMerck Sharp & Dohme LLCRecruitingBreakthrough BleedingBrazil
Clinical Trials on Norgestimate/Ethinyl Estradiol tablet
-
University of Colorado, DenverRecruiting
-
University of PennsylvaniaSociety of Family PlanningTerminatedCystic Fibrosis Exacerbations While on and Off Hormonal ContraceptionUnited States
-
Janssen Research & Development, LLCCompleted
-
Ortho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Gilead SciencesCompleted
-
Janssen-Cilag Ltd.,ThailandCompleted
-
Johnson & Johnson Taiwan LtdCompleted
-
University of VermontUniversity of Vermont Medical CenterCompletedVenous Thrombosis
-
McNeil Consumer & Specialty Pharmaceuticals, a...Completed
-
Enanta Pharmaceuticals, IncCovanceCompletedNASH - Nonalcoholic SteatohepatitisUnited States